A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
ConditionMetastatic Colorectal Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-130
SponsorAstraZeneca
About this trial
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Eligibility criteria
Qualifiers
Histopathologically confirmed colorectal adenocarcinoma.
Provision of FFPE tumor sample collected as per SoC.
Presence of measurable disease by RECIST 1.1 criteria.
ECOG performance status of 0 or 1.
Disqualifiers
Central nervous system metastases or spinal cord compression
Known history of severe allergy to any monoclonal antibody or study intervention.
Any unresolved toxicity CTCAE Grade ≥ 2 from a previous anticancer therapy.
History of another primary malignancy.
Trial design
Treatments tested in this trial
- Volrustomig
- FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
- Bevacizumab
Treatment groups
120 Participants
are divided into 2 treatment groupsLocations
76Australia
Research Site3002, East Melbourne Australia
Research Site2500, Wollongong Australia
Research Site5011, Woodville South Australia
Canada
Research SiteV8R 6V5, VictoriaBritish Columbia, Canada
Sponsors and collaborators
AstraZeneca
Lead sponsor
Parexel
Collaborator
Source ClinicalTrials.gov